# Stereotactic Ablative Radiotherapy for Oligometastatic Hepatocellular Carcinoma

> **NCT05173610** · PHASE2 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 40 (estimated)

## Conditions studied

- Oligometastasis Hepatocellular Carcinoma

## Interventions

- **RADIATION:** Radiation: Stereotactic body radiotherapy (SBRT)

## Key facts

- **NCT ID:** NCT05173610
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-28
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-09-27
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05173610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05173610, "Stereotactic Ablative Radiotherapy for Oligometastatic Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05173610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*